| Literature DB >> 30861315 |
Nicolas T Wirth1, Ekaterina Kozaeva1, Pablo I Nikel1.
Abstract
Pseudomonas species have become reliable platforms for bioproduction due to their capability to tolerate harsh conditions imposed by large-scale bioprocesses and their remarkable resistance to diverse physicochemical stresses. The last few years have brought forth a variety of synthetic biology tools for the genetic manipulation of pseudomonads, but most of them are either applicable only to obtain certain types of mutations, lack efficiency, or are not easily accessible to be used in different Pseudomonas species (e.g. natural isolates). In this work, we describe a versatile, robust and user-friendly procedure that facilitates virtually any kind of genomic manipulation in Pseudomonas species in 3-5 days. The protocol presented here is based on DNA recombination forced by double-stranded DNA cuts (through the activity of the I-SceI homing meganuclease from yeast) followed by highly efficient counterselection of mutants (aided by a synthetic CRISPR-Cas9 device). The individual parts of the genome engineering toolbox, tailored for knocking genes in and out, have been standardized to enable portability and easy exchange of functional gene modules as needed. The applicability of the procedure is illustrated both by eliminating selected genomic regions in the platform strain P. putida KT2440 (including difficult-to-delete genes) and by integrating different reporter genes (comprising novel variants of fluorescent proteins) into a defined landing site in the target chromosome.Entities:
Mesh:
Year: 2019 PMID: 30861315 PMCID: PMC6922521 DOI: 10.1111/1751-7915.13396
Source DB: PubMed Journal: Microb Biotechnol ISSN: 1751-7915 Impact factor: 5.813
Plasmids used in this work
| Name | Relevant features | Source or reference |
|---|---|---|
| pEMG | Suicide vector used for deletions in Gram‐negative bacteria; | Martínez‐García and de Lorenzo ( |
| pRK600 | Helper plasmid used for conjugation; | Kessler |
| pGNW2 | Derivative of vector pEMG carrying | This work |
| pGNW4 | Derivative of vector pGNW2; SmR | This work |
| pGNW6 | Derivative of vector pGNW2; GmR | This work |
| pGNW2 | Derivative of vector pGNW2 carrying HRs to delete | This work |
| pGNW4 | Derivative of vector pGNW4 carrying HRs to delete | This work |
| pGNW6 | Derivative of vector pGNW6 carrying HRs to delete | This work |
| pGNW2 | Derivative of vector pGNW2 carrying HRs to delete | This work |
| pSEVA2313 | Expression vector; | This work |
| pS2313 | Derivative of vector pSEVA2313 carrying | This work |
| pS2313 | Derivative of vector pSEVA2313 carrying | This work |
| pS2313 | Derivative of vector pSEVA2313 carrying | This work |
| pS2313 | Derivative of vector pSEVA2313 carrying | This work |
| pGNW2 | Derivative of vector pGNW2 carrying | This work |
| pGNW2 | Derivative of vector pGNW2 carrying HRs to insert | This work |
| pGNW2 | Derivative of vector pGNW2 carrying HRs to insert | This work |
| pGNW2 | Derivative of vector pGNW2 carrying HRs to insert | This work |
| pGNW4 | Derivative of vector pGNW4 carrying HRs to insert | This work |
| pGNW6 | Derivative of vector pGNW6 carrying HRs to insert | This work |
| pSEVA128S | Helper plasmid; | Aparicio |
| pSEVA228S | Helper plasmid; | Aparicio |
| pSEVA428S | Helper plasmid; | Aparicio |
| pSEVA628S | Helper plasmid; | Aparicio |
| pSEVA1213S | Helper plasmid; | This work |
| pSEVA6213S | Helper plasmid; | This work |
| pSEVA448 | Expression vector; | Silva‐Rocha |
| pSEVA421.Cas9tr | Cloning vector; | Aparicio |
| pS448 | Derivative of vector pSEVA448 used for CRISPR‐Cas9 counterselection; | This work |
| pS448 | Derivative of vector pS448 | This work |
a. Plasmids can be obtained from Addgene (http://www.addgene.org) with the following deposit numbers: pGNW2 (122086), pGNW4 (122088), pGNW6 (122093), pSEVA1213S (122095), pSEVA6213S (122094) and pS448·CsR (122096).
b. Antibiotic markers: Amp, ampicillin; Cm, chloramphenicol; Km, kanamycin; Sm, streptomycin; and Gm, gentamicin. HRs, homology regions.
Figure 1Overview diagram of the genome engineering procedure in Pseudomonas putida. On the delivery date of the designed oligonucleotides, homologous regions are amplified from the Pseudomonas genome and assembled into a suitable pGNW vector. The resulting plasmid is then delivered into E. coli λpir cells via chemical transformation. Furthermore (if applicable), a synthetic spacer, completing a specific synthetic guide RNA (sgRNA), is separately prepared and cloned into the CRISPR‐Cas9―vector pS448·CsR. On day 2, E. coli transformants are screened for the correct pGNW insert size (and spacer insertion in vector pS448·CsR, if applicable) via colony PCR, the resulting amplicons are sent out for sequencing, and the corresponding clones are used to inoculate liquid cultures. Day 3 includes the verification of sequence integrity of the insert in the pGNW vector, the purification of individual plasmids, and their delivery into Pseudomonas either via electroporation or tri‐parental mating. The resulting co‐integrants are enriched in liquid LB cultures during the course of day 4 and transformed with either an I‐SceI―bearing plasmid or plasmid pS448·CsR carrying an appropriate sgRNA. Finally, Pseudomonas colonies without fluorescence are tested on day 5 for their genotype via colony PCR.
Figure 2Workflow for the construction of derivatives of pGNW vectors for genome engineering. Two homology regions (HR1 and HR2), each one spanning about 500 bp and located upstream and downstream of the mutagenesis region (MR), are amplified from genomic DNA of Pseudomonas via PCR. Modifications (i.e. insertions or substitutions) are introduced between the HRs as overhangs in the oligonucleotides (indicated in the diagram with a red star) or as additional DNA fragments (not shown). For gene deletions, the sequences of the HRs are designed so that they frame the genome sequence to be deleted. HR1 and HR2 are fused and integrated into one of the pGNW vectors via assembly (shown here) or alternative molecular cloning techniques. The thereby assembled pGNW plasmid is then introduced into E. coli DH5α λpir. Individual E. coli clones obtained after transformation are examined for green fluorescence on a blue‐light transilluminator and checked for the correct pGNW insert size via colony PCR, and the purified amplicon is sent for sequencing. After the sequence integrity is confirmed, pGNW plasmids are purified from the respective E. coli strain and saved for the next step.
Figure 3Workflow for targeted genomic manipulations in Pseudomonas. Pseudomonas cells are transformed with pGNW via electroporation or tri‐parental mating. One to five individual green fluorescent colonies are combined and enriched in liquid LB medium cultures and transformed either with plasmid pSEVAX2YS or with a derivative of vector pS448·CsR carrying an appropriate sgRNA. Note that the antibiotic resistance could be different depending on the vector chosen for the deletion. Expression of the gene encoding the I‐SceI meganuclease mediates the excision of the pGNW sequence from the chromosome, leading to non‐fluorescent colonies under blue‐light exposure. These clones are tested via colony PCR and sequencing for a revertant (i.e. wild‐type) or mutant genotype. Asterisks indicate the relevant genotypes as well as the molecular events happening in the Pseudomonas chromosome (A) during the corresponding steps of the genome engineering protocol (B).
Figure 4Plasmid curing after successful genome engineering of Pseudomonas. The biomass from a single mutant Pseudomonas colony is used to inoculate 5–10 ml of LB medium and the suspension is incubated at 30°C with shaking. Two to three times per day, a small volume of this culture is transferred into fresh LB medium. After 2–3 days (i.e. at least six passages), the cells are isolated on LB medium agar plates and tested for the loss of plasmids based on their antibiotic‐resistance profile.
Figure 5Deletion of nicX in Pseudomonas putida KT2440.
A. Proposed degradation pathway of nicotinic acid in P. putida based on the information available in the literature (Jiménez et al., 2008). The key metabolic intermediate accumulating upon elimination of nicX (encoding 2,5‐dihydroxypyridine‐5,6‐dioxygenase) is highlighted in green. The targeted, in‐frame deletion of nicX is indicated by a red cross.
B. Schematic representation of the molecular mechanism for the integration of the suicide plasmid pGNW ·ΔnicX in the chromosome of strain KT2440 as well as the second recombination leading to either a revertant or a mutant genotype. Note that the antibiotic resistance could be different depending on the vector chosen for the deletion.
C. Representative picture of a section of an LB medium agar plate (containing 10 μg ml−1 Gm and 5 mM nicotinic acid) seeded with an isolate of strain KT2440 that was previously co‐integrated with the suicide plasmid pGNW2·ΔnicX and transformed with the helper plasmid pSEVA6213S. The accumulation of 2,5‐dihydroxypyridine (green‐to‐brown pigmented colonies) can be easily detected by visual inspection of the plates. The picture was taken after incubation for 16 h at 30°C followed by 24 h at 4°C. The black arrows indicate colonies formed by P. putida ΔnicX cells; the white arrows identify colonies displaying a revertant (i.e. wild‐type) genotype.
Figure 6Integration of different fluorescent proteins into a landing pad in the chromosome of Pseudomonas putida KT2440.
A. Genes encoding the fluorescent proteins mRFP1, mOrange2, mTurquoise2, msfGFP, and mBFP2 [placed under transcriptional control of a P () regulatory element], were integrated into a chosen landing site in the chromosome of P. KT2440 using the insertional vectors pGNW2, pGNW4, or pGNW6. After selection of co‐integrants, the second homologous recombination was mediated by the inducible expression of the gene encoding the I‐SceI meganuclease from pSEVAX28S vectors.
B. Images of the plates were taken after incubation for 16 h at 30°C followed by 7 days at 4°C to allow for proper fluorescent protein maturation. ‐integrated colonies showed no visible fluorescence under blue‐light exposure (not shown). The blue arrows indicate colonies of mutated strains displaying different integrated fluorescent proteins; white arrows identify colonies of cells displaying a revertant genotype (i.e. wild‐type) without fluorescence.
Bacterial strains used in this study
| Strain | Relevant characteristics | Reference or source |
|---|---|---|
|
| ||
| DH5α | Cloning host; F– λ–
| Hanahan and Meselson ( |
| DH5α λ | Cloning host; same as DH5α but λ | Platt |
| HB101 | Helper strain used for tri‐parental mating; F–
| Boyer and Roulland‐Dussoix ( |
|
| ||
| KT2440 | Wild‐type strain, derived from | Bagdasarian |
| KT2440 Δ | Same as KT2440, but with an in‐frame deletion of the | This work |
| KT2440 Δ | Same as KT2440, but with an in‐frame deletion of the | This work |
| KT·LPR | Same as KT2440, but carrying a | This work |
| KT·LPG | Same as KT2440, but carrying a | This work |
| KT·LPB | Same as KT2440, but carrying a | This work |
| KT·LPO | Same as KT2440, but carrying a | This work |
| KT·LPT | Same as KT2440, but carrying a | This work |
a. Antibiotic markers: Nal, nalidixic acid; and Sm, streptomycin.